Back to list


University of North Carolina at Chapel Hill


The purpose of this study is to measure the safety and effectiveness of Exenatide Once Weekly (EQW) in children and teens with Type 2 Diabetes Mellitus (T2DM). This medication is injected one time per week to help manage Hemoglobin A1c and potentially help with weight loss. EQW is already approved for use in adults to manage T2DM.


Diabetes, Pediatrics


Drug or Biologic



10 - 17 years


Study Population

Children and Teens, ages 10-17 years, with Type 2 Diabetes Mellitus


Nina Jain
Associate Professor
Pediatrics - Endocrinology

For questions, contact:

Chayla Hart
(919) 962-3965

Recruitment Period End

June 28, 2019


Primary Location
Clinical & Translational Research Center

Study Qualifications

Gender Male

Age Range 10 - 17 years

Participant qualification(s) Participants should: - Have an official diagnosis of Type 2 Diabetes Mellitus. - Be currently treated with oral antidiabetic medication (like metformin), insulin, or diet & exercise alone. Parents should be able to read and understand study forms and assist participant with taking study medication.

Not eligible if: Participants should not: - Have a major medical condition that could potentially affect study participation (examples: liver disease, kidney disease, chronic infection, etc.). - Have ever taken Exenatide, Liraglutide, or similar medications. - Abuse drugs or alcohol.

Number of Visits

    » 11 In person visit(s)

    1 Screening Clinic Visit, 9 Study Medication Clinic Visits, 1 Follow-Up Clinic Visit

    » 3 Remote visit(s)

    3 Phone Visits

Participation Period

62 Weeks


Parent and participant stipend offered per attended visit.

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.